Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG + Q mix protects Balb/c mice from infection

Parasite Immunology

Volumn 26, Issue 6-7, 2004, Pages 283-293

  Parody, N ^a   Soto, M ^a   Requena, J M ^a   Álonso, Carlos ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Antigens; Leishmania; Q protein; Vaccine

Indexed keywords

BCG VACCINE; DOUBLE STRANDED DNA; EPITOPE; FREUND ADJUVANT; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN M; OLIGODEOXYNUCLEOTIDE; PARASITE ANTIGEN; Q PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; CPG ISLAND; DOG; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMORAL IMMUNITY; LEISHMANIA INFANTUM; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; LIVER; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; PLASMIDS; PROTOZOAN PROTEINS; SPLEEN;

ANIMALIA; CANIS FAMILIARIS; LEISHMANIA INFANTUM; MYCOBACTERIUM BOVIS BCG; PROTOZOA;

EID: 9644272761     PISSN: 01419838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0141-9838.2004.00711.x     Document Type: Article

References (56)

1. Mosmann TR & Coffman RL. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 1989; 46: 111-147.
2. Coffman RL, Seymour BW, Lebman DA, et al. The role of helper T cell products in mouse B cell differentiation and isotype regulation. Immunol Rev 1988; 102: 5-28.
3. Finkelman FD, Holmes J, Katona IM, et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 1990; 8: 303-333.
4. Shearer GM & Clerici M. Vaccine strategies: selective elicitation of cellular or humoral immunity? Trends Biotechnol 1997; 15: 106-109.
5. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA & Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348-2357.
6. Cherwinski HM, Schumacher JH, Brown KD & Mosmann TR. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J Exp Med 1987; 166: 1229-1244.
7. Warren HS, Vogel FR & Chedid LA. Current status of immunological adjuvants. Anna Rev Immunol 1986; 4: 369-388.
8. Karagouni EE & Hadjipetrou-Kourounakis L. Regulation of isotype immunoglobulin and interleukin production by adjuvants in vitro. J Clin Lab Immunol 1990; 33: 29-39.
9. Victoratos P, Yiangou M, Avramidis N & Hadjipetrou L. Regulation of cytokine gene expression by adjuvants in vivo. Clin Exp Immunol 1997; 109: 569-578.
10. Comoy EE, Capron A & Thyphronitis G. In vivo induction of type 1 and 2 immune responses against protein antigens. Int Immunol 1997; 9: 523-531.
11. Singh M & O'Hagan D. Advances in vaccine adjuvants. Nat Biotechnol 1999; 17: 1075-1081.
12. Aebischer T, Wolfram M, Patzer SI, Ilg T, Wiese M & Overath P. Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants. Infect Immun 2000; 68: 1328-1336.
13. Sacks D & Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002; 2: 845-858.
14. Snapper CM, Finkelman FD & Paul WE. Regulation of IgG1 and IgE production by interleukin 4. Immunol Rev 1988; 102: 51-75.
15. Moon HB, Severinson E, Heusser C, Johansson SG, Moller G & Persson U. Regulation of IgG1 and IgE synthesis by interleukin 4 in mouse B cells. Scand J Immunol 1989; 30: 355-361.
16. Purkerson JM & Isakson PC. Interleukin 5 (IL-5) provides a signal that is required in addition to IL-4 for isotype switching to immunoglobulin (Ig) G1 and IgE. J Exp Med 1992; 175: 973-982.
17. Cocks BG, de Waal Malefyt R, Galizzi JP, de Vries JE & Aversa G. IL-13 induces proliferation and differentiation of human B cells activated by the CD40 ligand. Int Immunol 1993; 5: 657-663.
18. Satoskar A, Bluethmann H & Alexander J. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect Immun 1995; 63: 4894-4899.
19. Alexander J, Carter KC, Al-Fasi N, Satoskar A & Brombacher F. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol 2000; 30: 2935-2943.
20. + T-cell responses. Nat Med 2003; 9: 1287-1292. Epub 2003 September 21.
21. Stager S, Alexander J, Carter KC, Brombacher F & Kaye PM. Both interleukin-4 (IL-4) and IL-4 receptor alpha signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity. Infect Immun 2003; 71: 4804-4807.
22. + T cells. IL 5 is essential for induction of antigen-specific antibody responses by TH2 but not TH1 clones. Eur J Immunol 1990; 20: 2219-2227.
23. Sato Y, Roman M, Tighe H, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996; 273 (5273): 352-354.
24. Klinman DM, Yamshchikov G & Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 1997; 158: 3635-3639.
25. Roman M, Martin-Orozco E, Goodman JS, et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997; 3: 849-854.
26. Krieg AM. Mechanisms and application of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta 1999; 1489: 107-116.
27. Van Uden J & Raz E. Immunostimulatory DNA and applications to allergic diseases. J Allergy Clin. Immunol 1999; 104: 902-910.
28. Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol 1999; 73: 329-368.
29. Yang J, Kawamura I, Zhu H & Mitsuyama M. Involvement of natural killer cells in nitric oxide production by spleen cells after stimulation with Mycobacterium bovis BCG. Study of the mechanism of the different abilities of viable and killed BCG. J Immunol 1995; 155: 5728-5735.
30. Saito S & Nakano M. Nitric oxide production by peritoneal macrophages of Mycobacterium bovis BCG-infected or non-infected mice: regulatory role of T lymphocytes and cytokines. J Leukoc Biol 1996; 59: 908-915.
31. Molano I, Alonso MG, Miron C, et al. A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet Immunol Immunopathol 2003; 92: 1-13.
32. Matzinger P. An innate sense of danger. Ann N Y Acad Sci 2002; 961: 341-342.
33. Schijns V. Immunological concepts of vaccine adjuvant activity. Current Opin Immunol 2000; 12: 456-463.
34. Wallin RP, Lundqvist A, More SH, von Bonin A, Kiessling R & Ljunggren HG. Heat-shock proteins as activators of the innate immune system. Trends Immunol 2002; 23: 130-135.
35. Rico AI, Angel SO, Alonso C & Requena JM. Immunostimulatory properties of the Leishmania infantum heat shock proteins HSP70 and HSP83. Mol Immunol 1999; 36: 1131-1139.
36. Asea A, Kraeft SK, Kurt-Jones EA, et al. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 2000; 6: 435-442.
37. Soto M, Requena JM, Quijada L & Alonso C. Multicomponent chimeric antigen for serodiagnosis of canine visceral leishmaniasis. J Clin Microbiol 1998; 36: 58-63.
38. Rico AI, Del Real G, Soto M, et al. Characterization of the immunostimulatory properties of Leishmania infantum HSP70 by fusion to the Escherichia coli maltose-binding protein in normal and nu/nu BALB/c mice. Infect Immun 1998; 66: 347-352.
39. Scott P, Pearce E, Natovitz P & Sher A. Vaccination against cutaneous leishmaniasis in a murine model. II. Immunologic properties of protective and nonprotective subfractions of soluble promastigote extract. J Immunol 1987; 139: 3118-3125.
40. Melby PC, Yang YZ, Cheng J & Zhao W. Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani. Infect Immun 1998; 66: 18-27.
41. Skeiky YA, Coler RN, Brannon M, et al. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 2002; 20: 3292-3303.
42. Reis e Sousa C, Sher A & Kaye P. The role of dendritic cells in the induction and regulation of immunity to microbial infection. Curr Opin Immunol 1999; 11: 392-399.
43. Jakob T, Walker PS, Krieg AM, Udey MC & Vogel JC. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 1998; 161: 3042-3049.
44. Lipford GB, Sparwasser T, Zimmermann S, Heeg K & Wagner H. CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J Immunol 2000; 165: 1228-1235.
45. Shah JA, Darrah PA, Ambrozak DR, et al. Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice. J Exp Med 2003; 198: 281-291.
46. de Oliveira Mendes C, Paraguai de Souza E, Borja-Cabrera GP, et al. IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniasis. Vaccine 2003; 21: 2589-2597.
47. Rico AI, Angel SO & Alonso C & Requena JM. Immuno-stimulatory properties of the Leishmania infantum heat shock proteins HSP70 and HSP83. Mol Immunol 1999; 36: 1131-1139.
48. Baumgarth N. A two-phase model of B-cell activation. Immunol Rev 2000; 176: 171-180.
49. Suzue K & Young RA. Heat shock proteins as immunological carriers and vaccines. EXS 1996; 77: 451-465.
50. Soto M, Alonso C & Requena JM. The Leishmania infantum acidic ribosomal protein LiP2a induces a prominent humoral response in vivo and stimulates cell proliferation in vitro and interferon-gamma (IFN-gamma) production by murine splenocytes. Clin Exp Immunol 2000; 122: 212-218.
51. Stacey KJ & Blackwell JM. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect Immun 1999; 67: 3719-3726.
52. + T cell responses and protection against Leishmania major infection. J Exp Med 2002; 195: 1565-1573.
53. Cotterell SE, Engwerda CR & Kaye PM. Leishmania donovani infection initiates T cell-independent chemokine responses, which are subsequently amplified in a T cell-dependent manner. Eur J Immunol 1999; 29: 203-214.
54. Lehmann J, Enssle KH, Lehmann I, Emmendorfer A & Lohmann-Matthes ML. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice. J Interferon Cytokine Res 2000; 20: 63-77.
55. Melby PC, Tabares A, Restrepo BI, Cardona AE, McGuff HS & Teale JM. Leishmania donovani. evolution and architecture of the splenic cellular immune response related to control of infection. Exp Parasitol 2001; 99: 17-25.
56. Iborra S, Soto M, Carrion J, et al. The Leishmania infantum acidic ribosomal protein PO administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice. Infect Immun 2003; 71: 6562-6572.